DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Avastin (Bevacizumab) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

DRUG INTERACTIONS

No formal drug interaction studies with anti‑neoplastic agents have been conducted. In Study 1, patients with colorectal cancer were given irinotecan/5‑FU/leucovorin (bolus‑IFL) with or without AVASTIN. Irinotecan concentrations were similar in patients receiving bolus‑IFL alone and in combination with AVASTIN. The concentrations of SN38, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus‑IFL in combination with AVASTIN when compared with bolus‑IFL alone. In Study 1, patients receiving bolus‑IFL plus AVASTIN had a higher incidence of NCI‑CTC Grade 3–4 diarrhea and neutropenia. Due to high inter‑patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent irinotecan and AVASTIN is uncertain.

In Study 6, based on limited data, there did not appear to be a difference in the mean exposure of either carboplatin or paclitaxel when each was administered alone or in combination with AVASTIN. However, 3 of the 8 patients receiving AVASTIN plus paclitaxel/carboplatin had substantially lower paclitaxel exposure after four cycles of treatment (at Day 63) than those at Day 0, while patients receiving paclitaxel/carboplatin without AVASTIN had a greater paclitaxel exposure at Day 63 than at Day 0.

OVERDOSAGE

The highest dose tested in humans (20 mg/kg IV) was associated with headache in nine of 16 patients and with severe headache in three of 16 patients.

CONTRAINDICATIONS

None.

REFERENCES

  1. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti‑vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–9.

AVASTIN®

(Bevacizumab)

For Intravenous Use

Manufactured by:

Genentech, Inc.

1 DNA Way

South San Francisco, CA 94080-4990

7455311

LV0017

4835702

Initial U.S. Approval: February 2004

Code Revision Date: September 2007

© 2007 Genentech, Inc

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014